75 results about "Immunoadsorption" patented technology

The invention belongs to the field of immunological detection, and provides a double-antibody sandwich ELISA kit for detecting the content of human beta-NGF. The enzyme-linked immunosorbent assay kit constructed by the invention is based on a double-antibody sandwich method, and is combined with a biotin-streptavidin signal amplification system and an enzyme developing amplification system, so that the detection sensitivity and specificity are greatly improved, and low-content samples can be accurately and quickly detected. The kit shows excellent stability and specificity and can be used for quantitatively detecting the content of beta-NGF in samples such as human serum, cell supernatant or tissue homogenate, so that an objective detection basis is provided for diagnosis, curative effect evaluation and pathogenesis research of related diseases.

The invention discloses a variable region amino acid sequence of a monoclonal antibody of a West Nile virus non-structural protein NS1 and application of the variable region amino acid sequence, and belongs to the technical field of medicines. According to the invention, West Nile virus non-structural protein NS1 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the West Nile virus non-structural protein NS1 are screened from rabbit spleen cells through flow sorting, and a signal peptide and a variable region gene fragment of an antibody are cloned through reverse transcription-polymerase chain reaction; according to the present invention, the non-structural protein NS1 of flaviviridae flaviviridae virus is taken as a template, and is connected with a constant region gene to an expression vector, and after mammalian cell expression and purification, the monoclonal antibody which has high affinity and is not combined with the non-structural protein NS1 of other eight viruses of flaviviridae flaviviridae virus is obtained through enzyme-linked immunosorbent assay; the monoclonal antibody has application value in diagnosis and prevention and treatment of West Nile virus infection.

The invention discloses application of hydrogen-rich water in preparation of a drug for treating Duchenne type muscular dystrophy, and particularly relates to the technical field of medicines.The random control experiment is adopted, homologous c57 mice serve as a normal control group, mdx mice are randomly divided into a model group and a hydrogen-rich water group, and the exercise ability is evaluated through a four-limb holding power test and a rotating bar test; detecting mouse creatine kinase by an enzyme-linked immunosorbent assay; carrying out hematoxylin-eosin, NADH-tetrazole reductase and improved Goori three-color dyeing, and carrying out cytochrome C oxidase, succinate dehydrogenase and SDH-COX combined dyeing to observe the pathological change of the skeletal muscle tissue; the invention discloses that the muscle injury condition of a Duchenne type muscular dystrophy model mouse is improved by the hydrogen-rich water through a mitochondrial protection mechanism, and the hydrogen-rich water has a relatively high application prospect and a relatively high economic value.

Described herein are methods and kits for the detection of platelet-activating pathogenic antibodies in samples from patients suspected of having platelet-activating antibodies or non-HIT anti-PF4 antibody mediated syndromes using platelets and polyvinyl sulfonate or salts thereof. Upon platelet activation, thrombospondin-1 (TSP1), a platelet granule protein, is released and can be detected using a TSP1 antigen capture enzyme linked immunosorbent assay (ELISA) to accurately measure platelet activation.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

In accordance with at least one aspect of this disclosure, a method for preparing a patient for a diagnostic procedure and / or for receiving a therapy using a disease targeted drug is provided. The method can include the steps of a) identifying one or more soluble targets detectable in plasma of the patient; and b) extracorporeally removing the soluble targets from the plasma of the patient. Extracorporeally removing the soluble targets from the plasma of the patient can include using plasmapheresis or immunoadsorption to prepare a patient for a procedure using disease targeted treatment or diagnostics. Additionally, or alternatively, dose modulation can be used to proportionally increase the concertation of the diagnostic / treatment agent relative to the concentration of the soluble target in the blood, improving the outcome treatment and diagnostic procedures over conventional methods.

The invention discloses a yellow fever virus envelope protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. Yellow fever virus envelope protein E expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the yellow fever virus envelope protein E are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the monoclonal antibody with high neutralizing activity and capable of completely protecting mice from yellow fever virus lethal attack is obtained by using the monoclonal antibody as a template, connecting the monoclonal antibody and the constant region gene to an expression vector, carrying out mammalian cell expression and purification, and carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse virus attack experiment, such that the monoclonal antibody has high neutralizing activity and can completely protect mice from yellow fever virus lethal attack; the monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention relates to the field of biological medicines, and discloses application of serum EPSTI1 in preparation of a product for diagnosing liver cancer and evaluating whether a liver cancer patient is resistant to a revatinib or not. The invention provides a detection means which is convenient and rapid in sampling, small in risk and relatively low in cost, the content of EPSTI1 in serum is detected through an enzyme-linked immunosorbent assay, a liver cancer patient and a non-liver cancer patient can be effectively distinguished, and a lovatinib drug-resistant liver cancer patient and a non-drug-resistant liver cancer patient can be effectively distinguished. Prognosis analysis shows that the serum EPSTI1 can be used as a marker for evaluating the prognosis state of the liver cancer patient taking the lenvatinib, and has important significance in improving the survival rate of the liver cancer patient.

The application discloses a nano antibody against Ebola virus VP40 protein and application thereof in Ebola virus detection, wherein the nano antibody against Ebola virus VP40 protein is a 3E07 antibody. The nano antibody against Ebola virus VP40 protein prepared by the application has the characteristics of high sensitivity and wide binding spectrum. A double antibody sandwich enzyme-linked immunosorbent assay method constructed by 3E07 and 3F06 antibodies can efficiently detect VP40 proteins and virus-like particles of various Ebola virus subtypes such as Zaire, Sudan and Beni, wherein the detection sensitivity of the Ebola virus VP40 protein of Zaire type can reach 0.039 ng / mL, and the antibody combination has a wide application prospect in the diagnosis and pathogen detection of Ebola virus disease.

The invention relates to an anti-ovarian antibody chemiluminiscence kit and a preparation method thereof. The kit comprises amino magnetic beads coated with anti-ovarian antibody recombinant protein, anti-human immune globulin labeled by alkaline phosphatase, an anti-ovarian antibody calibrator and a chemiluminiscence substrate. The method has the beneficial effects that the 7-day acceleration stability of the AOAb coated amino magnetic bead is improved to 95% or above, the signal-to-noise ratio is high, the correlation coefficient is greater than 0.999, the test repeatability CV is less than 3.5%, the reagent correlation and the magnetic bead stability can be better improved, and the test result is ensured to be accurate. By optimizing the amino magnetic bead cross-linking agent, 60 clinical samples are tested and compared with the result of a comparison manufacturer, the total coincidence rate is as high as 98%, and false positive can be effectively reduced. Meanwhile, a detection system is formed by matching with a Guilin superior chemiluminescence immunoassay analyzer IA-260, the testing amount per hour reaches 130 tests, and compared with a traditional colloidal gold immunochromatography method and a traditional enzyme-linked immunosorbent assay method, the detection speed is greatly increased, and the result optimization accuracy is greatly improved.

The invention relates to a nano antibody for specifically recognizing a tacrolimus-antibody compound and application of the nano antibody, and belongs to the technical field of biological detection. A variable region of the nano antibody has three complementary determining regions CDR1, CDR2 and CDR3, can specifically recognize a tacrolimus-antibody compound, and can be used for detecting drugs by a double-antibody sandwich method; the kit is widely suitable for various immunodetection technologies such as an enzyme-linked immunosorbent assay (ELISA), a chemiluminescence immunoassay (CLIA), an electrochemical luminescence immunoassay (ECLIA), a fluorescence immunoassay (FIA), an immunochromatography test strip method and the like. According to the method, the limitation of a traditional competition method is overcome, high-sensitivity, high-specificity and high-stability detection is realized, the method can be adapted to various detection platforms, and a portable pretreatment process without centrifugation can also be realized.

The invention belongs to the technical field of biotechnology and protein determination, and particularly relates to confining liquid as well as a preparation method and application thereof. Modified bovine serum albumin and recombinant casein polypeptide are used as core components of the confining liquid, hydroxypropyl-beta-cyclodextrin, polyglycerol fatty acid ester and other auxiliary components are added, and the confining liquid is prepared through a specific technology. The modified bovine serum albumin and the recombinant casein polypeptide have a synergistic effect, so that active sites of the detection carrier can be efficiently sealed; the stabilizing agent and other components are supplemented, so that the stability and compatibility of the confining liquid are improved. The confining liquid is simple and convenient in preparation process, controllable in cost, suitable for various detection carriers such as elisa plates and nitrocellulose membranes, capable of reducing non-specific binding and improving detection sensitivity, and suitable for various biological detection scenes such as enzyme-linked immunosorbent assay.

The invention belongs to the technical field of bioengineering, and particularly relates to a preparation method and application of a calprotectin S100A8 / A9 dimer mouse monoclonal antibody, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO. 28-30. According to the present invention, the S100A8 / A9 heterodimer protein with biological activity and immunostimulation function is prepared, the protein is used to immunize mice, the specific gene engineering antibody of the S100A8 / A9 heterodimer protein is prepared, the antibody pair with high sensitivity is screened, and the calprotectin S100A8 / A9 double-antibody sandwich enzyme-linked immunosorbent assay method is preliminarily developed;

The application belongs to the field of biology and relates to a nanobody targeting calexcin and a preparation method and application thereof, the nanobody targeting calexcin is successfully screened and prepared, and the nanobody-HRP fusion protein used for affinity identification in an enzyme-linked immunosorbent assay is successfully expressed; in combination with a phage-assisted continuous and discontinuous directed evolution (PACE) system, the nanobody screened is subjected to directed evolution, and stable mutation sites are found through sequence alignment analysis; it is proved through an indirect enzyme-linked immunosorbent assay and a luciferase complementation assay that the affinity of the nanobody after evolution to calexcin is improved by about 2 times.

This invention provides a serum protein biomarker for early screening and diagnosis of pancreatic ductal adenocarcinoma. The serum protein biomarker is one or a combination of two or more autoantibodies against tumor-associated antigens HEXB, TXLNA, and SLAMF6. The invention also provides the application of reagents, kits, and analytical methods for detecting the serum protein biomarker. This invention screens for autoantibodies against pancreatic ductal adenocarcinoma-associated antigens. By measuring the expression levels of these indicators in the serum of patients with pancreatic ductal adenocarcinoma, healthy controls, and controls with benign pancreatic diseases, the screened anti-HEXB, anti-TXLNA, and anti-SLAMF6 autoantibodies can distinguish between pancreatic ductal adenocarcinoma, healthy controls, and benign pancreatic diseases. Furthermore, this invention designs and optimizes combinations of tumor-associated antigens for the diagnosis of pancreatic ductal adenocarcinoma. Applying the optimized antigens to an ELISA kit and detecting serum anti-TAA autoantibodies using an indirect enzyme-linked immunosorbent assay (ELISA) can accurately identify patients with pancreatic ductal adenocarcinoma, healthy controls, and patients with benign pancreatic diseases.

The present invention relates to a polypeptide derived from natural tridegin by structural modification, which may serve as an inhibitor of plasma coagulation factor XIIIa, and to pharmaceutical compositions comprising such polypeptide. The present invention further refers to such polypeptide or pharmaceutical composition for use in a method for treating or preventing a thrombotic event in a patient. Moreover, the invention relates to an endoprosthesis or an enzyme-linked immunosorbent assay (ELISA) plate coated with a polypeptide of the present invention. Furthermore, the invention also encompasses a recombinant fusion protein comprising this polypeptide linked to a fibrinolytic enzyme such as streptokinase, nattokinase or tPAs via a flexible peptide linker containing a thrombin-cleavable site. This construct allows selective inhibition of FXIIIa within a thrombus, while enabling thrombin-triggered release of the fibrinolytic enzyme to induce localized fibrinolysis, thereby achieving targeted dual-action thrombolytic therapy.

The invention relates to application of arachidonic acid (ARA) in preparation of a medicine for treating sleep disorder related spontaneous abortion. Peripheral blood lipid metabolism sequencing analysis finds that the ARA content in peripheral blood serum of a patient suffering from sleep disorder and repeated pregnancy loss is most obviously reduced compared with that of a patient suffering from normal sleep and normal pregnancy; an enzyme-linked immunosorbent assay test shows that the content of ARA in decidua stromal cells (DSCs) of a patient with sleep disorder and repeated pregnancy loss is remarkably reduced compared with that of a pregnant person with normal sleep; after the endometrial stromal cells (ESCs) are subjected to ARA treatment, the in-vitro decidualization level is increased; the ARA inhibitor can be used for inhibiting the in-vitro deciduation level of the ESCs; compared with a mouse with normal sleep, the content of ARA in peripheral blood and DSCs of a mouse with sleep disorder is remarkably reduced, decidua is poor, and the abortion rate is increased; supplementing ARA can improve decidua disorder and high abortion rate caused by sleep disorder. Therefore, a potential target and a new idea are provided for diagnosis and treatment of repeated pregnancy loss related to sleep disorder.

This invention belongs to the field of biodetection technology, specifically relating to a material for detecting anti-Caspr1 antibodies and its preparation method. The invention constructs an expression plasmid capable of highly expressing the Caspr1 antigen, transfects it into HEK293T cells, and modifies the original antigen sequence during construction to achieve normal membrane expression. Subsequently, a modified cell culture protocol is used to obtain a material for detecting anti-Caspr1 antibodies based on cellular immunofluorescence assay. This invention, based on cellular immunofluorescence, avoids the limitations of flow cytometry, which is complex and requires expensive equipment. By modifying the protein expression mode to normal membrane expression, it avoids cell permeabilization, avoids false negatives caused by antigen conformational changes in enzyme-linked immunosorbent assay (ELISA) and Western blotting, and avoids false negatives caused by transmembrane expression due to transfection with the original Caspr1 sequence.

The present application relates to the technical field of liquid milk production and processing, and discloses a production method and system of high-activity immunoglobulin liquid milk, which comprises the following steps: screening qualified raw milk and performing milk clarification and defatting through enzyme-linked immunosorbent assay combined with high-performance liquid chromatography, obtaining defatted milk by dynamically adjusting the centrifugal speed and storing the defatted milk at low temperature, periodically detecting the defatted milk by dynamically regulating the storage temperature, and obtaining qualified defatted milk; extracting immunoglobulin, regulating the subtype ratio of the immunoglobulin to adapt to special medical scenarios, and then performing glycosylation modification and desensitization, obtaining immunoglobulin modified liquid and sterile substrate through synergistic sterilization treatment; dynamically adjusting the speed for mixing and correcting the physicochemical properties, performing sterile filling and sealing after optimizing the sensory quality, comprehensively detecting the packaged product, and obtaining qualified finished products; dynamically regulating cold chain parameters according to the activity of immunoglobulin, monitoring the whole process, classifying and stacking, optimizing the adaptability of the production system, treating production wastewater, and recycling residual immunoglobulin.

The invention discloses a chikungunya virus monoclonal antibody and application thereof in preparation of preventive and therapeutic antibody drugs, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

A disposable bioassay diagnostic cartridge for performing enzyme-linked immunosorbent assay for a single patient in whole blood and plasma where the cartridge has a plurality of wells. The cartridge includes a pipette tip with internal sidewalls disposed in one well of the plurality of wells, the internal sidewalls being pretreated and coated with antibodies, a reagent mixture disposed in another well of the plurality of wells, the reagent mixture comprising at least one reagent selected from the group consisting of pH stabilizer, ionic catalyst control agent, ionic intracellular inhibitory control agent, detergent, negative control agent, chelating agent, and biocide preservative, antibody, and conjugate stabilizing agent. At least a chromogenic substrate and visualizing reagent disposed in an integrated cuvette of the plurality of wells. It also includes the detection of the hemoglobin amount in the blood sample so a correction for plasma amount in a sample can be performed.

The present application relates to the field of immunoassay technology, discloses a product for early diagnosis of sepsis and its application, the composition of the product for early diagnosis of sepsis includes detecting SAA1 protein and PDL1 + The product for detecting the content of exosome in sample is based on antigen-antibody specific immune binding to detect SAA1 protein and PDL1 + The product for detecting the content of exosome in sample, the detection method adopted by the detection product is selected from one of fluorescence immunoassay, enzyme-linked immunosorbent assay, colloidal gold immunochromatography, chemiluminescence immunoassay, electrochemical immunoassay and nanopore-based immunosensing detection method, the product for early diagnosis of sepsis improves the accuracy of early diagnosis of sepsis and disease condition evaluation in a double-index cooperative manner, effectively solves the technical bottleneck that the existing sepsis detection method is insufficient in sensitivity, poor in specificity and difficult to meet the requirements of early precise diagnosis and dynamic disease condition evaluation.

The utility model discloses a medical electrochemical detection test strip with an anti-interference effect. The medical electrochemical detection test strip sequentially comprises a substrate, a four-electrode system, a sensitive layer, an immunoadsorption layer, a first blood filtering layer and a hydrophilic layer from bottom to top, the hydrophilic layer is prepared by carrying out Plasma hydrophilic treatment on PET (Polyethylene Terephthalate); the first blood filtering layer is made of a glass fiber material; the immunoadsorption layer comprises an anti-interference pad, the anti-interference pad is made of polyester fibers, and the anti-interference pad contains an anti-interference test; the sensitive layer comprises a cellulose acetate fiber pad membrane of which the outer surface is loaded with an antibody; the four-electrode system is composed of a working electrode, a reference electrode, a counter electrode and a contrast electrode, and the four-electrode system is formed by printing carbon paste or silver paste on the substrate. According to the electrochemical detection test strip with the structure, the anti-interference performance can be effectively improved, and the detection accuracy and precision are greatly improved.

This invention discloses a monoclonal antibody against Oit3 protein in mouse hepatic sinusoidal endothelial cells or its antigen-binding fragment and its applications, belonging to the fields of biotechnology and medical immunology. The monoclonal antibody or its antigen-binding fragment comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region contains HCDR1, HCDR2, and HCDR3 with amino acid sequences as shown in SEQ ID NO. 3~SEQ ID NO. 5; the light chain variable region contains LCDR1, LCDR2, and LCDR3 with amino acid sequences as shown in SEQ ID NO. 8~SEQ ID NO. 10. This monoclonal antibody and the recombinant fluorescent antibody exhibit high affinity and high specificity, and can be effectively applied to enzyme-linked immunosorbent assay (ELISA), Western blotting, and immunofluorescence detection. They can serve as important antibody tools for basic research on mouse hepatic sinusoidal endothelial cells and for exploring the mechanisms of liver diseases. Based on its variable region sequence, a recombinant fluorescent antibody, Oit3-scFv-GFP, was also constructed. This recombinant fluorescent antibody enables one-step direct immunofluorescence staining, providing a convenient tool for in situ visualization of mouse hepatic sinusoidal endothelial cells.

The invention discloses a litopenaeus vannamei Vg polyclonal antibody as well as a preparation method, a quantitative detection method and application thereof, and relates to the field of biotechnology and immunodetection. The polyclonal antibody is obtained by immunizing a polypeptide antigen containing an amino acid sequence SEQ ID NO: 1 (CPTKYEIETEGEKV), and the polyclonal antibody can specifically recognize the litopenaeus vannamei Vg. The invention provides and establishes a novel non-double antibody sandwich enzyme-linked immunosorbent assay (ELISA) method for the first time, and the core of the novel non-double antibody sandwich enzyme-linked immunosorbent assay (ELISA) method is that a Litopenaeus vannamei VgR ligand binding structural domain is used as a solid-phase capture molecule, and the polyclonal antibody is used as a detection antibody to form a receptor-ligand-antibody detection mode. The method effectively avoids the technical bottleneck that paired antibodies are difficult to prepare in a traditional method, and has the advantages of wide linear range and good repeatability.

The invention belongs to the field of biomedical examination, and particularly provides a kit for rapidly detecting CD3 molecules of peripheral T cells and a detection method of the kit. The kit comprises a specific anti-CD3 monoclonal antibody, a second antibody, alkaline phosphatase labeled streptavidin, a buffer solution, a color developing agent and a nuclear counterstaining agent. High-sensitivity and high-specificity detection of CD3 molecules is realized through recognition of a specific anti-CD3 monoclonal antibody and cell surface CD3 molecules and application of an enzyme-linked immunosorbent assay technology. The specific detection method comprises the steps of sample treatment, capture reaction, detection reaction, color development and result analysis. The kit disclosed by the invention has the advantages of simplicity and convenience in operation, rapidness in detection, high sensitivity, good specificity and the like, is suitable for laboratory and clinical detection, and provides an efficient and reliable detection tool for immunological research, autoimmune disease diagnosis and tumor immunotherapy effect evaluation.

The invention discloses a method for detecting cucumber green mottle mosaic virus (CGMMV) in soil aiming at the detection technical requirements of important plant pathogens in the soil. The method comprises the following steps: sampling to-be-detected field soil, adding clear water with the same weight, stirring until soil particles are uniform, standing, filtering supernatant liquid, adding polyethylene glycol (the molecular weight is 6000-8000, and the final concentration is 6-10%) and sodium chloride (the final concentration is 1-2%), carrying out ice bath treatment for 2 hours to overnight, centrifuging 12000 g of the solution for 1 hour to settle virus particles, and dissolving and precipitating with distilled water to obtain virus-enriched liquid; the CGMMV can be directly detected by using various conventional detection methods, including an RT-PCR (Reverse Transcription-Polymerase Chain Reaction) method, a fluorescent quantitative PCR method, a colloidal gold immunochromatography method, enzyme-linked immunosorbent assay (ELISA) and the like. According to the method, on the premise of ensuring the reliability and the accuracy, the detection steps are simplified, and the cost and the time are saved. The method is applied to detection of the CGMMV in soil of a cucurbitaceae crop planting field, can effectively guide disease prevention and control in production, and prevents diffusion and harm of the CGMMV.

The invention discloses a fluorescence immunoadsorption method for detecting an O-type foot-and-mouth disease virus VP1 protein antibody and application, and relates to the technical field of genetic engineering, and the method is characterized by comprising the following steps: S1, preparing O-type foot-and-mouth disease virus VP1 protein by using a prokaryotic expression system; s2, preparing an anti-O type foot-and-mouth disease VP1 protein monoclonal antibody capable of recognizing a VP1 protein epitope; s3, coupling quantum dots with the anti-O-type foot-and-mouth disease VP1 protein monoclonal antibody to obtain a novel fluorescent probe; and S4, quantitatively detecting the O-type foot-and-mouth disease virus antibody through a fluorescence immunoadsorption method. According to the method, quantum dots and an O-type foot-and-mouth disease VP1 protein resisting monoclonal antibody are coupled to serve as a novel fluorescent probe, a fluorescence immunoassay method is established and used for quantitative detection of the O-type foot-and-mouth disease virus antibody, and compared with a traditional indirect competitive enzyme-linked immunosorbent assay, the method is more sensitive.

In accordance with at least one aspect of this disclosure, a method for preparing a patient for a diagnostic procedure and / or for receiving a therapy using a disease targeted drug is provided. The method can include the steps of a) identifying one or more soluble targets detectable in plasma of the patient; and b) extracorporeally removing the soluble targets from the plasma of the patient. Extracorporeally removing the soluble targets from the plasma of the patient can include using plasmapheresis or immunoadsorption to prepare a patient for a procedure using disease targeted treatment or diagnostics. Additionally, or alternatively, dose modulation can be used to proportionally increase the concertation of the diagnostic / treatment agent relative to the concentration of the soluble target in the blood, improving the outcome treatment and diagnostic procedures over conventional methods.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application of the chikungunya virus envelope E2 protein monoclonal antibody in preparation of preventive and therapeutic antibody drugs, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.